NCT06569095 Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
| NCT ID | NCT06569095 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Myelodysplastic Syndromes |
| Study Type | OBSERVATIONAL |
| Enrollment | 163 participants |
| Start Date | 2024-12-09 |
| Primary Completion | 2027-12-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 163 participants in total. It began in 2024-12-09 with a primary completion date of 2027-12-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Presently, multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) have been used for disease load, including measurable residual disease (MRD), monitoring in patients with myelodysplastic syndrome (MDS). MFC is the most commonly method for disease load evaluation. In patients with acute myeloid leukemia, leukemia stem cells (LSCs) determined using MFC for leukemia load and MRD detection is superior to traditional MFC method. In the investigators previous single center study, the investigators demonstrated that detection of disease load, including MRD, by MFC in patients with MDS-EB is superior to predict outcomes after allogeneic stem cell transplantation. Here, the investigators will perform a multi-center, prospective clinical trial to investigate the predictive values of MDS-SC in patients with MDS-EB who received allografting.
Eligibility Criteria
Inclusion Criteria: * Patients with Myelodysplastic syndromes; * Between 15 and 70 years old; * Subjects are able to provide written informed consent. Exclusion Criteria: * Subjects who cannot comply with the study; * Patient has severe cardiac (ejection fraction \<50%), hepatic (total bilirubin \>34μmol/L, ALT, AST \>2x upper limit of normal) or renal (blood creatinine \>130μmol/L) disease； * Uncontrolled serious infection; * Other conditions that do not tolerate transplantation or other therapies.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06569095 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 70 Years, studying Myelodysplastic Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06569095 currently recruiting?
Yes, NCT06569095 is actively recruiting participants. Contact the research team at rmcyj@bjmu.edu.cn for enrollment information.
Where is the NCT06569095 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Wuhan, China, Zhengzhou, China.
Who is sponsoring the NCT06569095 clinical trial?
NCT06569095 is sponsored by Peking University People's Hospital. The trial plans to enroll 163 participants.